Publications by authors named "Linda Gomm"
Readiness to Implement Novel SACT: Tumor-Infiltrating Lymphocyte Therapy.
Semin Oncol Nurs
February 2025
Objectives: Adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) therapy has demonstrated promising results in clinical trials. Recognizing the growing potential of cell therapies for solid tumors, oncology services need to prepare for an increasing number of trials and, in the near future, optimize patient access to TIL. Consultation with clinical trials professionals in England, however, highlighted low organizational readiness and significant knowledge gaps for use of adoptive cell therapy.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on a new immunotherapy approach called T4, designed to treat locally advanced/recurrent head and neck squamous cell carcinoma (HNSCC) by targeting upregulated ErbB proteins in tumor cells.
- This phase 1 trial involved injecting engineered CAR T-cells directly into tumors, with doses provided in escalating amounts, and showcased that these T-cells could be successfully manufactured from patient blood without toxic effects.
- In terms of results, the treatment showed manageable side effects (mostly mild) and demonstrated localized persistence of T-cells in the tumor site, however, it did not halt rapid tumor progression in patients.
Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited.
Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19.
Design, Setting, And Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin.